Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Compare

7,624 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TEVA Analyst Ratings

Strong Buy

10 Buy

1 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Teva

Pharmaceutical

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TEVA Stock 12 Month Forecast

Average Price Target

$31.22

▲(4.80% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Teva Pharmaceutical in the last 3 months. The average price target is $31.22 with a high forecast of $35.00 and a low forecast of $28.00. The average price target represents a 4.80% change from the last price of $29.79.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","25":"$25","36":"$36","19.5":"$19.5","30.5":"$30.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$31.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$28.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,19.5,25,30.5,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.72,27.356923076923074,27.993846153846153,28.63076923076923,29.267692307692307,29.904615384615383,30.54153846153846,31.178461538461537,31.815384615384616,32.45230769230769,33.08923076923077,33.72615384615385,34.363076923076925,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.72,27.066153846153846,27.412307692307692,27.75846153846154,28.104615384615382,28.45076923076923,28.796923076923076,29.143076923076922,29.48923076923077,29.835384615384616,30.18153846153846,30.527692307692305,30.873846153846152,{"y":31.22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.72,26.818461538461538,26.916923076923077,27.015384615384615,27.113846153846154,27.212307692307693,27.310769230769232,27.409230769230767,27.507692307692306,27.606153846153845,27.704615384615384,27.803076923076922,27.90153846153846,{"y":28,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.65,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.73,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.46,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.26,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.38,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.06,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.48,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.72,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$35.00

Average Price Target$31.22

Lowest Price Target$28.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matthew Dellatorre

Goldman Sachs

$28→$31

Buy

4.06%

Upside

Reiterated

12/09/25

Goldman Sachs Remains a Buy on Teva Pharmaceutical (TEVA)

Jason Gerberry

Bank of America Securities

$29→$32

Buy

7.42%

Upside

Reiterated

12/08/25

Bank of America Securities Remains a Buy on Teva Pharmaceutical (TEVA)Our $32 PO (from $29) reflects 10.5x our 2026 EBITDA outlook. Reiterate Buy.

Glen Santangelo

Barclays

$35

Buy

17.49%

Upside

Initiated

12/08/25

Teva initiated with an Overweight at BarclaysTeva initiated with an Overweight at Barclays

David Amsellem

Piper Sandler

$30

Buy

0.70%

Upside

Reiterated

12/05/25

Teva Pharmaceutical (TEVA) Gets a Buy from Piper Sandler

Louise Chen

Scotiabank

$35

Buy

17.49%

Upside

Initiated

12/04/25

Teva initiated with an Outperform at ScotiabankTeva initiated with an Outperform at Scotiabank

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

11/26/25

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Teva Pharmaceutical (NYSE: TEVA)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$29

Buy

-2.65%

Downside

Reiterated

11/26/25

Jefferies Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)

Yatin Suneja

Guggenheim

―

Hold

―

Reiterated

11/18/25

Analysts Conflicted on These Healthcare Names: Teva Pharmaceutical (NYSE: TEVA) and Purple Biotech (NASDAQ: PPBT)

Ashwani Verma

UBS

$26→$29

Buy

-2.65%

Downside

Reiterated

11/06/25

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), Establishment Labs Holdings (NASDAQ: ESTA) and RxSight (NASDAQ: RXST)

Les Sulewski

Truist Financial

$25→$32

Buy

7.42%

Upside

Reiterated

11/06/25

Truist Financial Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)

Chris Schott

J.P. Morgan

$26→$28

Buy

-6.01%

Downside

Reiterated

11/06/25

Teva price target raised to $28 from $26 at JPMorganTeva price target raised to $28 from $26 at JPMorgan

Rajesh Kumar

HSBC

$24→$20

Buy

-32.86%

Downside

Reiterated

04/28/25

Teva price target lowered to $20 from $24 at HSBCTeva price target lowered to $20 from $24 at HSBC

Jasper Hellweg

Argus Research

$20

Buy

-32.86%

Downside

Reiterated

01/30/25

Teva Pharmaceutical (TEVA) Gets a Buy from Argus Research

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matthew Dellatorre

Goldman Sachs

$28→$31

Buy

4.06%

Upside

Reiterated

12/09/25

Goldman Sachs Remains a Buy on Teva Pharmaceutical (TEVA)

Jason Gerberry

Bank of America Securities

$29→$32

Buy

7.42%

Upside

Reiterated

12/08/25

Bank of America Securities Remains a Buy on Teva Pharmaceutical (TEVA)Our $32 PO (from $29) reflects 10.5x our 2026 EBITDA outlook. Reiterate Buy.

Glen Santangelo

Barclays

$35

Buy

17.49%

Upside

Initiated

12/08/25

Teva initiated with an Overweight at BarclaysTeva initiated with an Overweight at Barclays

David Amsellem

Piper Sandler

$30

Buy

0.70%

Upside

Reiterated

12/05/25

Teva Pharmaceutical (TEVA) Gets a Buy from Piper Sandler

Louise Chen

Scotiabank

$35

Buy

17.49%

Upside

Initiated

12/04/25

Teva initiated with an Outperform at ScotiabankTeva initiated with an Outperform at Scotiabank

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

11/26/25

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX) and Teva Pharmaceutical (NYSE: TEVA)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$29

Buy

-2.65%

Downside

Reiterated

11/26/25

Jefferies Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)

Yatin Suneja

Guggenheim

―

Hold

―

Reiterated

11/18/25

Analysts Conflicted on These Healthcare Names: Teva Pharmaceutical (NYSE: TEVA) and Purple Biotech (NASDAQ: PPBT)

Ashwani Verma

UBS

$26→$29

Buy

-2.65%

Downside

Reiterated

11/06/25

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), Establishment Labs Holdings (NASDAQ: ESTA) and RxSight (NASDAQ: RXST)

Les Sulewski

Truist Financial

$25→$32

Buy

7.42%

Upside

Reiterated

11/06/25

Truist Financial Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)

Chris Schott

J.P. Morgan

$26→$28

Buy

-6.01%

Downside

Reiterated

11/06/25

Teva price target raised to $28 from $26 at JPMorganTeva price target raised to $28 from $26 at JPMorgan

Rajesh Kumar

HSBC

$24→$20

Buy

-32.86%

Downside

Reiterated

04/28/25

Teva price target lowered to $20 from $24 at HSBCTeva price target lowered to $20 from $24 at HSBC

Jasper Hellweg

Argus Research

$20

Buy

-32.86%

Downside

Reiterated

01/30/25

Teva Pharmaceutical (TEVA) Gets a Buy from Argus Research

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Teva Pharmaceutical

1 Month

xxx

Success Rate

10/18 ratings generated profit

Average Return

+1.55%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +1.55% per trade.

3 Months

xxx

Success Rate

13/18 ratings generated profit

Average Return

+8.15%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 72.22% of your transactions generating a profit, with an average return of +8.15% per trade.

1 Year

Ashwani VermaUBS

Success Rate

16/18 ratings generated profit

Average Return

+37.41%

reiterated a buy rating last month

Copying Ashwani Verma's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +37.41% per trade.

2 Years

xxx

Success Rate

18/18 ratings generated profit

Average Return

+78.83%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +78.83% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TEVA Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TEVA has received 16 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. TEVA average Analyst price target in the past 3 months is 31.22.

Each month's total comprises the sum of three months' worth of ratings.

TEVA Financial Forecast

TEVA Earnings Forecast

Next quarter’s earnings estimate for TEVA is $0.66 with a range of $0.58 to $0.78. The previous quarter’s EPS was $0.78. TEVA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year TEVA has Performed in-line its overall industry.

TEVA Sales Forecast

Next quarter’s sales forecast for TEVA is $4.39B with a range of $4.14B to $4.62B. The previous quarter’s sales results were $4.49B. TEVA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year TEVA has Performed in-line its overall industry.

TEVA Stock Forecast FAQ

What is TEVA’s average 12-month price target, according to analysts?

Based on analyst ratings, Teva Pharmaceutical Industries Limited’s 12-month average price target is 31.22.

What is TEVA’s upside potential, based on the analysts’ average price target?

Teva Pharmaceutical Industries Limited has 4.80% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TEVA a Buy, Sell or Hold?

Teva Pharmaceutical Industries Limited has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.

What is Teva Pharmaceutical Industries Limited’s price target?

The average price target for Teva Pharmaceutical Industries Limited is 31.22. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $35.00 ,the lowest forecast is $28.00. The average price target represents 4.80% Increase from the current price of $29.79.

What do analysts say about Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of TEVA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

TEVA Analyst Ratings

TEVA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Teva Pharmaceutical

TEVA Analyst Recommendation Trends

TEVA Financial Forecast

TEVA Earnings Forecast

TEVA Sales Forecast

TEVA Stock Forecast FAQ

Detailed List of Analyst Forecasts